171 related articles for article (PubMed ID: 36685039)
41. Asymptomatic Leishmania infection in HIV-positive outpatients on antiretroviral therapy in Pernambuco, Brazil.
Guedes DL; Justo AM; Barbosa Júnior WL; Silva EDD; Aquino SR; Lima Junior MSDC; Montarroyos U; Bezerra GSN; Vieira AVB; Pereira VRA; Medeiros ZM
PLoS Negl Trop Dis; 2021 Jan; 15(1):e0009067. PubMed ID: 33476331
[TBL] [Abstract][Full Text] [Related]
42. Higher levels of TNF and IL-4 cytokines and low miR-182 expression in visceral leishmaniasis-HIV co-infected patients.
Barbosa Júnior WL; Justo AM; Aguiar Dos Santos AM; de Lorena VMB; do Carmo RF; de Melo FL; de Medeiros ZM; Vasconcelos LRS
Parasite Immunol; 2020 Apr; 42(4):e12701. PubMed ID: 31990371
[TBL] [Abstract][Full Text] [Related]
43. Epidemiological profile of patients co-infected with visceral leishmaniasis and HIV/AIDS in Northeast, Brazil.
Viana GMC; Silva MACND; Garcia JVS; Guimarães HD; Arcos GF; Santos AVA; Paixão PVD; Nascimento MDDSB; Galvão CS
Rev Soc Bras Med Trop; 2017; 50(5):613-620. PubMed ID: 29160507
[TBL] [Abstract][Full Text] [Related]
44. Arginase activity in the blood of patients with visceral leishmaniasis and HIV infection.
Takele Y; Abebe T; Weldegebreal T; Hailu A; Hailu W; Hurissa Z; Ali J; Diro E; Sisay Y; Cloke T; Modolell M; Munder M; Tacchini-Cottier F; Müller I; Kropf P
PLoS Negl Trop Dis; 2013; 7(1):e1977. PubMed ID: 23349999
[TBL] [Abstract][Full Text] [Related]
45. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
Salih NA; van Griensven J; Chappuis F; Antierens A; Mumina A; Hammam O; Boulle P; Alirol E; Alnour M; Elhag MS; Manzi M; Kizito W; Zachariah R
Trop Med Int Health; 2014 Feb; 19(2):146-52. PubMed ID: 24433217
[TBL] [Abstract][Full Text] [Related]
46. Visceral Leishmaniasis and HIV Co-Infection in Northwest Ethiopia: Antiretroviral Treatment and Burden of Disease among Patients Enrolled in HIV Care.
van Griensven J; Simegn T; Endris M; Diro E
Am J Trop Med Hyg; 2018 Feb; 98(2):486-491. PubMed ID: 29210347
[TBL] [Abstract][Full Text] [Related]
47. Prevalence estimates of human immunodeficiency virus (HIV) infection among visceral leishmaniasis infected people in Northwest Ethiopia: a systematic review and meta-analysis.
Mohebali M; Yimam Y
BMC Infect Dis; 2020 Mar; 20(1):214. PubMed ID: 32164607
[TBL] [Abstract][Full Text] [Related]
48. Does timing of antiretroviral treatment influence treatment outcomes of visceral leishmaniasis in Northwest Ethiopia?
Aderie EM; Diro E; Zachariah R; da Fonseca MS; Abongomera C; Dolamo BL; Ritmeijer K
Trans R Soc Trop Med Hyg; 2017 Mar; 111(3):107-116. PubMed ID: 28633331
[TBL] [Abstract][Full Text] [Related]
49. Serum Levels of Soluble CD40 Ligand and Neopterin in HIV Coinfected Asymptomatic and Symptomatic Visceral Leishmaniasis Patients.
Adriaensen W; Abdellati S; van Henten S; Gedamu Y; Diro E; Vogt F; Mengesha B; Adem E; Kestens L; van Griensven J
Front Cell Infect Microbiol; 2018; 8():428. PubMed ID: 30619775
[TBL] [Abstract][Full Text] [Related]
50. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
Diro E; Lynen L; Mohammed R; Boelaert M; Hailu A; van Griensven J
PLoS Negl Trop Dis; 2014 May; 8(5):e2875. PubMed ID: 24854196
[TBL] [Abstract][Full Text] [Related]
51. Factors associated with relapse and hospital death in patients coinfected with visceral leishmaniasis and HIV: a longitudinal study.
Costa LDLN; Lima US; Rodrigues V; Lima MIS; Silva LA; Ithamar J; Azevedo CMPS
BMC Infect Dis; 2023 Mar; 23(1):141. PubMed ID: 36882732
[TBL] [Abstract][Full Text] [Related]
52. Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts.
Kubar J; Marty P; Lelièvre A; Quaranta JF; Staccini P; Caroli-Bosc C; Le Fichoux Y
AIDS; 1998 Nov; 12(16):2147-53. PubMed ID: 9833855
[TBL] [Abstract][Full Text] [Related]
53. Low Plasma Lipids Are Associated with Relapsing and Lethal Visceral Leishmaniasis in HIV-Infected Patients.
Silva RVS; Uliana SRB; Yasunaka JKUY; Veloso CS; Sousa E; Ferreira MML; Carvalho VS; Ferreira GR; Costa DL; Costa CHN
Pathogens; 2024 May; 13(6):. PubMed ID: 38921748
[TBL] [Abstract][Full Text] [Related]
54. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
[TBL] [Abstract][Full Text] [Related]
55. Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study.
Kip AE; Blesson S; Alves F; Wasunna M; Kimutai R; Menza P; Mengesha B; Beijnen JH; Hailu A; Diro E; Dorlo TPC
J Antimicrob Chemother; 2021 Apr; 76(5):1258-1268. PubMed ID: 33677546
[TBL] [Abstract][Full Text] [Related]
56. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.
Ribera E; Ocaña I; de Otero J; Cortes E; Gasser I; Pahissa A
Am J Med; 1996 May; 100(5):496-501. PubMed ID: 8644760
[TBL] [Abstract][Full Text] [Related]
57. Lymphoproliferative response after stimulation with soluble leishmania antigen (SLA) as a predictor of visceral leishmaniasis (VL) relapse in HIV+ patients.
Castro A; Carrillo E; San Martín JV; Botana L; Molina L; Matía B; Fernandez L; Horrillo L; Ibarra-Meneses A; Sanchez C; Ruiz-Giardin JM; Moreno J
Acta Trop; 2016 Dec; 164():345-351. PubMed ID: 27693332
[TBL] [Abstract][Full Text] [Related]
58. Prevalence of Human Immunodeficiency Virus and associated factors among Visceral Leishmaniasis infected patients in Northwest Ethiopia: a facility based cross-sectional study.
Alemayehu M; Wubshet M; Mesfin N; Gebayehu A
BMC Infect Dis; 2017 Feb; 17(1):152. PubMed ID: 28212625
[TBL] [Abstract][Full Text] [Related]
59. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
[TBL] [Abstract][Full Text] [Related]
60. [Visceral leishmaniasis in immunocompromised patients].
Ramos A; Portero JL; Gazapo T; Yebra M; Portero F; Martín T
An Med Interna; 1998 Jun; 15(6):301-4. PubMed ID: 9656509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
